Let your Members of Congress know that you support the Medicaid VBPs for Patients (MVP) Act of 2025 (S. 1637)! One of AMCP's top federal policy priorities, this bipartisan bill will enhance access for Medicaid enrollees to new, high-cost therapies by modernizing the framework for value-based purchasing arrangements in Medicaid. The MVP Act builds on the existing “multiple best price” rule that allows manufacturers to report multiple best prices for drugs that are subject to value-based purchasing arrangements by clarifying that the best price under a value-based arrangement is the maximum possible price paid, assuming all patient outcome benchmarks are satisfied. This bill protects states from paying for high-cost treatments that are not effective. Learn more about the MVP Act on our Legislative & Regulatory Issues page. 

AMCP supports the MVP Act of 2025 and urges Congress to pass it. Please use the form below to encourage your Members of Congress to co-sponsor and vote for this important piece of legislation. You may also include a brief statement describing your experience with the impact that innovations like cell and gene therapies have on patients or the challenges with providing access using traditional payment methods in the space provided. If you see more than one message option displayed in the form, please enter your address at the bottom to show only the correct option. By sharing your experience, you will help shape AMCP’s narrative of why this bill should be enacted into law.